

1 Full title of manuscript: Prevalence and spectrum of germline *BRCA1* and *BRCA2* mutations in

2 multiethnic cohort of breast cancer patients in Brunei Darussalam

3

4 Short title of manuscript: *BRCA1* and *BRCA2* mutations in Brunei breast cancer patients

5

6 Siti Nur Idayu Matusin<sup>2</sup>, Nuramalina Mumin<sup>1</sup>, Hazirah Zainal Abidin<sup>3</sup>, Fatin Nurizzati Mohd Jaya<sup>4</sup>, Lu Zen

7 Huat<sup>1</sup>, Mas Rina Wati Haji Abdul Hamid<sup>1\*</sup>

8

9 <sup>1</sup>Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah (PAPRSB) Institute of Health Sciences, Universiti Brunei

10 Darussalam, Negara Brunei Darussalam

11

12 <sup>2</sup>Halalan Thayyiban Research Centre, Universiti Islam Sultan Sharif Ali, Jalan Tutong, Sinaut TB1741,

13 Negara Brunei Darussalam

14

15 <sup>3</sup>Ministry of Health, Commonwealth Drive, BB3910, Negara Brunei Darussalam

16

17 <sup>4</sup>ICC, AstraZeneca, Gaithersburg, MD, 20878, United States of America

18 \* Corresponding author

19 E-mail: rina.hamid@ubd.edu.bn

20

21 Author contributions

22 Conceptualised the original project: MRWHAH. Designed the experiments: MRWHAH, NM and SNIM.

23 Performed the experiments: SNIM, NM, HZA and FNMJ. Analysed the data: SNIM and LZH. Contributed

24 reagents/materials/samples/analysis tools: MRWHAH, LZH, SNIM, NM, HZA and FNMJ. Wrote the paper:  
25 SNIM. Reviewed the paper: MRWHAH

26

## 27 **Abstract**

28 This is the first genetic study of its kind in Brunei Darussalam. *BRCA1* and *BRCA2* genes are the most  
29 well-known and well described predictors of hereditary breast cancer due to their clinical importance.  
30 This study aimed to identify the prevalence and mutation spectrum of the *BRCA1* and *BRCA2* germline  
31 mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire  
32 coding region of *BRCA1* and *BRCA2* gene using Sanger sequencing and next-generation sequencing  
33 methods, and identified three pathogenic and one likely pathogenic mutations in the *BRCA2* gene. Of  
34 the 120 patients, 6 (5%) were *BRCA2* carriers which confirm that *BRCA2* carriers are more common in  
35 the Asian population compared to the Caucasian population. One *BRCA2* mutation observed only in the  
36 Chinese ethnicity of the Brunei breast cancer population contributes to the probability of the mutation  
37 being a founder effect in the Southern Chinese population. Brunei *BRCA2* carriers were more likely to  
38 have a positive family history of breast and/or ovarian cancers and have more than one family members  
39 in the first-degree relatives diagnosed with breast cancer.

40

## 41 **Introduction**

42 Breast cancer is the most common cancer affecting women worldwide with varying incidence rates  
43 across the world [1]. Among the breast cancer risk factors, genetic predisposition confers the highest  
44 risk in breast cancer progression [2]. About 5-10% of breast cancers are inherited with approximately  
45 30% of the inherited breast cancers were attributed to germline mutations in high penetrance breast  
46 cancer susceptibility genes, Breast Cancer susceptibility genes type 1 (*BRCA1*) [3] and Breast Cancer

47 susceptibility genes type 2 (*BRCA2*) [4]. *BRCA1* and *BRCA2* are tumour suppressor genes (TSGs) that  
48 function by suppressing the growth of tumour cells via multiple DNA damage and repair pathways in the  
49 cells [5-10]. Notably, the *BRCA1* protein is multi-functional as it also regulates cell cycle through a  
50 number of mechanisms [5,6,8,10-15].

51 *BRCA1* and *BRCA2* germline mutation carriers had an increased cumulative risk of 72% and 69%,  
52 respectively to develop breast cancer by 80 years old [16]. *BRCA1* and *BRCA2* carriers would also have an  
53 increased risk of developing ovarian, prostate, and pancreatic cancers [16]. Breast cancer patients who  
54 inherit germline mutations in these genes, in particular *BRCA1* carriers, are commonly associated with  
55 triple negative breast cancer (TNBC), diagnosed at an early age of onset ( $\leq 40$  years), diagnosed with  
56 bilateral breast cancer, having family history of breast and/or ovarian cancers in the first- and second-  
57 degree relatives, and having an ovarian cancer [17-21]. The discovery of these two genes being linked to  
58 breast and ovarian cancers has led to the increased importance of genetic testing where continuous  
59 research and development had ultimately resulted in *BRCA1* and *BRCA2* genetic tests available at a more  
60 affordable cost and with a higher sensitivity and specificity [22]. Moreover, increased awareness on  
61 available personalised treatment for affected patients such as olaparib, an oral poly ADP ribose  
62 polymerase (PARP) inhibitor, which has been shown to provide a significant benefit over standard  
63 therapy among the *BRCA* mutation-carrier patients [23-24], has led to the increasing demand for rapid  
64 *BRCA* testing preferably at the first diagnosis [22]. This rapid increase caused pressure for diagnostic  
65 laboratories to provide a genetic test with a shorter turnaround time [22]. The two most commonly  
66 used platform for DNA sequencing are Sanger sequencing and Next-generation sequencing (NGS).  
67 Although NGS has largely overtaken Sanger sequencing due to its cost-effective ability in screening a  
68 larger set of samples in parallel and simultaneous screening of multiple cancer susceptibility genes in  
69 one sample, Sanger sequencing is still used in laboratories today when the main objective is to screen a  
70 single gene only.

71 Brunei Darussalam is a small country (5,765 sq km) on the Borneo Island, located in the South-  
72 east Asia (SEA) region, bordering the South China Sea and East Malaysia [25]. The population is  
73 estimated over 400,000, comprises 66% Malay, 10% Chinese, 3% other indigenous and 21% other ethnic  
74 groups [25]. Breast cancer was one of the top three leading causes of cancer mortality among women in  
75 Brunei Darussalam with an incidence rate (age-standardized rate [ASR]) of 55.9 per 100,000 women  
76 which is the second highest among countries in the SEA region, but considerably lower compared to the  
77 Western Europe (ASR, 90.7) [1,26]. Notably, the incidence rate of breast cancer in Brunei varies by  
78 ethnicity, with the highest rate observed in Chinese (ASR, 60.4) [27], followed by Malays (ASR, 48.1) [27],  
79 and Others (ASR, 12.3) [28]. There has not been any formal study conducted on finding the contribution  
80 of genetic and non-genetic factors in the rising incidence of breast cancer in Brunei. Therefore,  
81 studying various aspects of breast cancer in the Brunei patients could help to understand and determine  
82 the probable cause that leads to the rise in the incidence of the disease in the population, and in  
83 planning a better health care for the Brunei population. The contribution of genetics in breast cancer  
84 specifically in the involvement of susceptibility genes has been continuously researched on in the  
85 Western and developed Asian countries resulting in many reports on the spectrum of variants within the  
86 susceptibility genes from all over the world. In the SEA region, the mutation spectrum of *BRCA1* and  
87 *BRCA2* genes in breast cancer has been studied in Singaporean [18,19,29-31], Malaysian [21,32-37],  
88 Filipino [38,39], Vietnamese [40,41], Thai [42,43], and Indonesian [44,45] populations leading to the  
89 discovery of novel pathogenic variants from different ethnicities, suggesting the mutation spectrum of  
90 the *BRCA1* and *BRCA2* genes are still understudied. Furthermore, a number of the variants identified in  
91 the SEA breast cancer populations has also been found in other populations such as the African,  
92 European and American suggesting that they are not specific to the reported population, implying the  
93 genetic heterogeneity and randomness of the mutations. Interestingly, most of the variants identified in  
94 the breast cancer population in East Malaysia which is also located on the Borneo Island [33] were not

95 identified in the West Malaysia population suggesting a difference in population genetics between East  
96 and West Malaysia.

97           Some of the variants identified in the Filipino breast cancer population who mostly were a  
98 combination of Malay and other population ancestry have also been proposed to be founder mutations  
99 due to the shared haplotype markers [39]. Currently, there are no genetic mutation data that report on  
100 the frequency of any genes related to breast cancer in Bruneian patients with or without family history.  
101 Thus, genetic contribution in breast cancer and other related cancers in Bruneian population remains  
102 uninvestigated. In this study, we investigated a population-based unselected series of Brunei breast  
103 cancer patients to determine the prevalence and spectrum of *BRCA1* and *BRCA2* mutations using Sanger  
104 and next-generation sequencing methods, and assess their association with sociodemographic,  
105 clinicopathological, and family history characteristics of the population.

106

## 107 **Materials and methods**

### 108 **Study population**

109 The study population includes unselected incident and prevalent breast cancer patients seen from 18<sup>th</sup>  
110 May 2012 until 30<sup>th</sup> January 2013, and from 23<sup>rd</sup> May 2016 until 19<sup>th</sup> November 2018 at The Brunei  
111 Cancer Centre (TBCC), Pantai Jerudong Specialist Centre (PJSC), the only cancer referral hospital in  
112 Negara Brunei Darussalam. Terminally-ill patients were excluded from the study. Among approximately  
113 567 patients attending clinics during this period of time, a total of 164 patients were approached and  
114 explained about the study. Patient information sheet was provided and 121 patients consented as the  
115 final study participants. All study participants signed informed consent document. Peripheral blood  
116 samples and demographic and family history data were collected from the consenting patients. One  
117 patient was later excluded due to insufficient DNA sample to complete the *BRCA1* and *BRCA2* mutation

118 analysis. Finally, 120 patients were included for the final analysis. Retrospective review of the study  
119 participants' medical and histopathology records was conducted at TBCC with authorized permission  
120 from relevant authorities from 1<sup>st</sup> November 2018 to 9<sup>th</sup> January 2019. The records were available in  
121 the form of hard printed copy. The study was approved by the Brunei Darussalam Ministry of Health's  
122 Medical and Health Research & Ethics Committee (MHREC).

123

## 124 ***BRCA1* and *BRCA2* mutational screening**

125 S1 Fig shows a flow chart of the strategy used to detect mutations in the *BRCA1* and *BRCA2* genes in the  
126 study population. The samples from the first 66 study participants (henceforth referred to as Batch 1)  
127 were analysed by Sanger sequencing while the samples from the last 54 study participants (henceforth  
128 referred to as Batch 2) were sequenced by next-generation sequencing (NGS).

129

## 130 **Sanger sequencing**

131 Samples sequenced using Sanger sequencing utilised two workflows, PCR amplified with designed  
132 primers, and PCR amplified using EasySeq<sup>TM</sup> PCR Plates for *BRCA1/2* Sequencing (Nimagen, The  
133 Netherlands).

134 In the first workflow, the gDNA extracted using Wizard Genomic DNA purification kit (Promega)  
135 was amplified using AmpliTaq<sup>®</sup> 360 DNA Polymerase kit (Applied Biosystems) prior to sequencing. The  
136 details of the primers and PCR conditions used in this study have been described elsewhere[46-48]. The  
137 PCR products were resolved onto 1% agarose gel for evaluation of successful amplifications without  
138 contamination. The remaining PCR products were then purified using QIAGEN QIAquick<sup>®</sup> PCR  
139 Purification Kit.

140 In the second workflow, the gDNA extracted was amplified using the EasySeq™ PCR Plates for  
141 *BRCA1/2* Sequencing (Nimagen, The Netherlands) following the manufacturer’s protocol. The plate was  
142 used for sequencing to screen for mutations in the complete coding region including  $\pm 50$ bp up- and  
143 downstream of each *BRCA1* and *BRCA2* genes’ coding exon. All of the primers in the columns were tailed  
144 with universal tails – forward primers with -21M13 (5’-TGATAAACGACGGCCAGT-3’) and reverse primers  
145 with M13Rev (5’-CAGGAAACAGCTATGACC-3’). PCR products from columns 1-10 were purified via  
146 ethanol/sodium acetate precipitation, and the pellets were resuspended with sterile water.

147 The purified PCR products from both workflows were used as the template for the Sanger  
148 sequencing reactions following the BigDye Terminator® v3.1 Cycle Sequencing Kit protocol (Applied  
149 Biosystems, USA). The sequencing products were purified using the Axygen AxyPrep™ Mag Dye Clean  
150 Up Kit. *BRCA1* and *BRCA2* Sanger sequencing was performed using the ABI 3500 Genetic Analyzer  
151 (Applied Biosystems, USA). The sequence data collected were processed and analysed using the 3500  
152 Sequencing Analysis Software v5.2. Purified PCR products from the first workflow were sent for Sanger  
153 sequencing (First BASE Laboratories, Malaysia).

154

## 155 **Next-generation sequencing (NGS)**

156 The DNA samples sequenced by NGS were outsourced to Cancer Research Malaysia (CRM) for *BRCA1*,  
157 *BRCA2*, *TP53*, and *PALB2* targeted panel sequencing. The HBOC\_4\_v2 gene panel used was developed  
158 by CRM and the University of Melbourne and was used to screen for coding exons  $\pm 2$  bp intronic  
159 sequence of the *BRCA1* (NM\_007294.3), *BRCA2* (NM\_000059.3), *PALB2* (NM\_024675.3), and *TP53*  
160 (NM\_000546.4) genes. Bioinformatic analysis was performed by CRM and the variant results excluding  
161 neutral polymorphisms were delivered upon completion.

162

## 163 **Bioinformatic analysis**

164 Sanger sequencing data obtained using Sequencing Analysis Software v5.2 and from First BASE  
165 Laboratories were aligned to the reference sequences of the gene obtained from the NCBI GenBank  
166 (*BRCA1* NCBI RefSeq = NG\_005905.2 and *BRCA2* NCBI RefSeq = NG\_012772.1) and nucleotide database  
167 (*BRCA1* NCBI RefSeq = NM\_007294.3 and *BRCA2* NCBI RefSeq = NM\_000059.3) using Variant Reporter  
168 Software v1.0 (Applied Biosystems, USA). All variants identified were annotated using the same  
169 software.

170 For samples sequenced by NGS, although CRM have analysed and validated the results, the data  
171 were re-analysed as neutral polymorphisms were not included in the provided results. The attainment  
172 of these results ensures the generation of a complete genetic variation profile for the patients.  
173 Integrative Genomics Viewer (IGV) v2.5.2 (Broad Institute) was used to view the binary files provided by  
174 CRM. The data were analysed using the public server at usegalaxy.eu [49]. Variants were called using  
175 varscan (Galaxy Version 2.4.2) and bcftools call (Galaxy Version 1.9+galaxy 1). The data generated by  
176 bcftools call were filtered using VCFfilter. All variants identified from NGS were annotated using the  
177 SNPeff Eff tool (Galaxy Version 4.3+T.galaxy1).

178 All variants identified from Sanger sequencing and NGS were annotated according to the  
179 nomenclature used by the Human Genome Variation Society (HGVS) recommendation guidelines, using  
180 the A of the ATG translation initiation codon as nucleotide +1. All identified missense variants were  
181 analysed *in silico* using SIFT, PolyPhen-2, CADD, FATHMM-MKL, and DANN to predict the effect of amino  
182 acid substitution. Each prediction tool scored the missense variant as damaging or benign/neutral. All  
183 variants identified in this study were also checked against the NCBI ClinVar, Varsome, and population  
184 frequency databases (gnomAD and 1000 genome).

185 All variants identified in this study, underwent thorough assessment and review of available  
186 evidence (e.g. database information, and *in silico* predictions) following the American College of Medical



187 Genetics and Genomics and the Association for Molecular Pathology (ACMG) standards and guidelines  
188 for the interpretation of sequence variants [50] to arrive at a final variant classification of either  
189 pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. In this  
190 study, a variant was considered a pathogenic damaging mutation if it was a protein-truncating mutation  
191 caused by deleterious or frameshift mutation, or a missense mutation which has a confirmed association  
192 with the disease, or a missense variant which has been classified as likely pathogenic according to the  
193 ACMG standards and guidelines. All pathogenic mutations identified using Sanger sequencing were  
194 confirmed by repeating the Sanger sequencing using an independent sample, while pathogenic  
195 mutations identified using NGS were re-sequenced using Sanger sequencing. We selectively Sanger  
196 sequenced only the pathogenic mutations identified using NGS via our own ABI 3500 Genetic Analyzer.  
197 Notably, CRM had confirmed all variants other than neutral polymorphisms by Sanger sequencing.

198

### 199 **Multiplex ligation-dependent probe amplification (MLPA)**

200 Samples from Batch 1 were screened for large genomic rearrangements by MPLA using the SALSA MLPA  
201 P002 BRCA1 and SALSA MLPA P090 BRCA2 probe mix following the manufacturers' protocol (MRC-  
202 Holland, Netherland). The MLPA analyses were performed by DNA Fragment Analysis on the ABI 3500  
203 Genetic Analyzer. Data obtained were comparatively analysed using Coffalyser Net software  
204 v.140721.1958 (MRC-Holland, Netherland).

205

### 206 **Statistical analyses**

207 Continuous data were presented as mean  $\pm$  standard deviation (SD) or median and range where  
208 applicable. Mann-Whitney test was used to compare differences between the medians in two or more  
209 independent groups respectively. Chi-square or Fisher exact test was used to analyse the association

210 between two independent variables in the population. The statistical analysis was performed using SPSS  
211 version 17.0 software for Windows. A p value <0.05 was considered statistically significant.

212

## 213 Results

214 This was the first study of its kind in the Brunei breast cancer patients. Of the 120 recruited breast  
215 cancer patients, 94 (78.3%) were Malays, 19 (15.8%) were Chinese, and 7 (5.8%) were others. The mean  
216 age at diagnosis was 49.1±10.51 years, with peak of breast cancer incidence occurred in the 51-60 years  
217 old age group, and one (0.8%) was a male breast cancer (Table 1).

218

219 **Table 1. Demographic characteristics, personal and family history of cancer of study population**

220 **(n=120).**

Characteristics	Mean (SD)	Frequency (%)
<b>Age at diagnosis (year)</b>	49.1 (10.51)	
<b>Gender</b>		
<b>Male</b>		1 (0.8)
<b>Female</b>		119 (99.2)
<b>Ethnicity</b>		
<b>Malay</b>		94 (78.3)
<b>Chinese</b>		19 (15.8)
<b>Others</b>		7 (5.8)
<b>Age at first diagnosis (year)</b>		
<b>≤30</b>		2 (1.7)
<b>31-40</b>		28 (23.3)

<b>41-50</b>		36 (30.0)
<b>51-60</b>		40 (33.3)
<b>≥61</b>		14 (11.7)
<b>Cancer history</b>		
<b>Personal history of cancer</b>		
<b>Bilateral breast cancer</b>		7 (5.8)
<b>Ovarian cancer</b>		2 (1.7)
<b>Endometrium cancer</b>		1 (0.8)
<b>Liver cancer</b>		1 (0.8)
<b>Family history of cancer</b>		
<b>Breast and/or ovarian cancer in 1° and 2° relatives</b>		36 (30.0)
<b>Breast and/or ovarian cancer in 3° and 4° relatives</b>		9 (7.5)
<b>Other cancer in any degree of relatives</b>		28 (23.3)
<b>No family history of cancer at all</b>		47 (39.2)
<b>No of 1° relatives with breast cancer</b>		
<b>0</b>		100 (83.3)
<b>1</b>		17 (14.2)
<b>≥2</b>		3 (2.5)
<b>No of 2° relatives with breast cancer</b>		
<b>0</b>		104 (86.7)
<b>1</b>		14 (11.7)
<b>≥2</b>		2 (1.7)
<b>No of 1° relatives with ovarian cancer</b>		

0	115 (95.8)
≥1	5 (4.2)
<b>No of 2<sup>o</sup> relatives with ovarian cancer</b>	
0	118 (98.3)
≥1	2 (1.7)

221 1<sup>o</sup>, First-degree; 2<sup>o</sup>, Second-degree; 3<sup>o</sup>, Third-degree; 4<sup>o</sup>, Fourth-degree; SD, Standard Deviation

222

223 Seven (5.8%), two (1.7%), one (0.8%), and one (0.8%) patients had personal history of bilateral breast  
224 cancers, ovarian cancer, endometrium cancer, and liver cancer, respectively. Assessment of family  
225 history of breast and/or ovarian cancers was made based on whether the affected family members of  
226 the patients were their first and/or second-degree relatives. Of the 120 cases, 36 (30.0%) had family  
227 history of breast and/or ovarian cancers in their first and/or second-degree relatives while 47 (39.2%)  
228 had no family history of cancers at all. Of patients with family history of breast cancer, 17 (14.2%) had  
229 one first-degree family member affected with breast cancer, and 3 (2.5%) had two first-degree relatives  
230 affected with breast cancer. For patients with family history of ovarian cancer, 5 (4.2%) and 2 (1.7%) had  
231 only one affected member in the first- and second-degree relatives respectively (Table 1).

232

### 233 ***BRCA1* and *BRCA2* mutations**

234 Of the 95 variants identified in the study population, 29 (30.5%) and 66 (69.5%) were *BRCA1* and *BRCA2*  
235 variants respectively (S1 – S4 Tables). Of the 29*BRCA1* and 66*BRCA2* variants, 11 (37.9%) and 22 (33.3%)  
236 were novel respectively (S2– S4 Tables). No large rearrangements were detected in this study.

237

## 238 **Prevalence of pathogenic mutations and VUS**

239 Our study identified three frameshift *BRCA2* deleterious mutations in 5 patients which led to the  
240 introduction of premature stop codon in the resulting *BRCA2* protein (S1 Table, Fig 1 and S2 Fig), and  
241 one likely pathogenic *BRCA2* missense mutation in one patient (S2 Table and Fig 1). Therefore, the  
242 overall prevalence of germline *BRCA1* and *BRCA2* carriers among Brunei breast cancer patients were 0%  
243 and 5%, respectively. All of the identified pathogenic and likely pathogenic mutations have been  
244 reported, and were rare in the general population (<0.05% in gnomAD and 1000 Genome). One of the  
245 *BRCA2* deleterious mutations (c.5164\_5165delAG) appeared to be a recurrent mutation.

246

247 **Fig 1. Schematic presentation of identified *BRCA2* pathogenic mutations among Brunei breast cancer**  
248 **cases.**

249

250 Excluding one patient with simultaneous germline pathogenic mutations, our study also identified  
251 9*BRCA1* and 32 *BRCA2* VUS in 10 and 31 patients, respectively (S3 Table). Thus, the prevalence of *BRCA1*  
252 and *BRCA2* VUS carriers among Brunei breast cancer patients were 8.3% and 25.8%, respectively. Four of  
253 the *BRCA1* VUS and 14 of the *BRCA2* VUS were novel while the others have been reported. Almost all of  
254 the reported VUS have no recorded data in the general population (S3 Table) while those that with data  
255 were found to be rare in the general population (<0.05% in gnomAD and 1000 Genome).

256

## 257 **Characteristics of Brunei's germline pathogenic *BRCA* carriers**

258 S5 Table shows the characteristics of the Brunei breast cancer patients with deleterious and damaging  
259 missense mutations. Collectively, one (16.7%) of the carriers was male while the rest were female. Two  
260 (33.3%) of the affected were diagnosed with bilateral breast cancer. The molecular subtype of the first  
261 breast cancer diagnosis showed that one (16.7%) patient was TNBC, one (16.7%) was Luminal A, while

262 the rest were Luminal B. Two (33.3%) of the carriers had an age at onset of  $\leq 40$  years while the others  
 263 were  $\geq 40$  years, and one (16.7%) of the carriers had no family history of cancers at all. The proportion of  
 264 our *BRCA1/2* carriers by ethnicity was 3/19 (15.8%) and 3/94 (3.2%) in Chinese and Malay, respectively.

265 There is no significant difference observed between the overall median age of diagnosis among  
 266 carriers (48 years) and non-carriers (49 years) ( $p=0.609$ , Table 2). Brunei *BRCA2* carriers were found to  
 267 be more likely to have family history of breast and/or ovarian cancer, and have  $\geq 1$  affected family  
 268 members in the first-degree with breast cancer ( $p = 0.027$  and  $p = 0.001$  respectively, Table 2). There are  
 269 no significant association between Brunei *BRCA2* carriers and other selected clinical characteristics in  
 270 Table 2.

271  
 272 **Table 2. Association analysis of Brunei breast cancer patients with pathogenic mutation with selected**  
 273 **clinical characteristics.**

	Total ( $n = 120$ )		<i>BRCA2</i> carriers ( $n = 6$ )		Non- <i>BRCA2</i> carriers ( $n = 114$ )		<i>p</i> -value <sup>a b</sup>
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	
<b>Age at diagnosis (years)</b>			<b>Median (range)</b>		<b>Median (range)</b>		0.609
			48 (31 – 59)		49 (27 – 71)		
<b>Age range (years)</b>							0.741
$\leq 40$	30	25.0	2	33.3	28	24.6	
41 – 50	36	30.0	1	16.7	35	30.7	
51 – 60	40	33.3	3	50.0	37	32.5	
$> 60$	14	11.7	0	0	14	12.3	
<b>Ethnicity</b>							0.089
Malay	94	78.3	3	50.0	91	79.8	

<b>Chinese</b>	19	15.8	3	50.0	16	14.0	
<b>Others</b>	7	5.8	0	0	7	6.1	
<b>Bilateral breast cancer</b>							
<b>Yes</b>	8	6.7	2	33.3	6	5.3	0.051
<b>No</b>	112	93.3	4	66.7	108	94.7	
<b>Estrogen Receptor (ER)</b>							
<b>Positive</b>	72	60.0	4	66.7	68	59.6	1
<b>Negative</b>	48	40.0	2	33.3	46	40.4	
<b>Progesterone Receptor (PR)</b>							
<b>Positive</b>	62	51.7	4	66.7	58	50.9	0.681
<b>Negative</b>	58	48.3	2	33.3	56	49.1	
<b>Her2</b>							
<b>Positive</b>	73	60.8	3	50.0	70	61.4	0.678
<b>Negative</b>	47	39.2	3	50.0	44	38.6	
<b>Triple negative breast cancer (TNBC)</b>							
<b>Yes</b>	15	12.5	1	16.7	14	12.3	0.559
<b>No</b>	105	87.5	5	83.3	100	87.7	
<b>Family history of cancer <sup>c</sup></b>							
<b>Yes</b>	72	60.0	5	83.3	67	58.8	0.400
<b>No</b>	48	40.0	1	16.7	47	41.2	
<b>Family history of breast and/or ovarian cancer</b>							

<b>Yes</b>	45	37.5	5	83.3	40	35.1	<b>0.027</b>
<b>No</b>	75	62.5	1	16.7	74	64.9	
<b>Number of affected first-degree relatives with breast cancer</b>							
	100	83.3	2	33.3	98	86.0	<b>0.001</b>
<b>0</b>	17	14.2	2	33.3	15	13.2	
<b>1</b>	3	2.5	2	33.3	1	0.9	
<b>≥2</b>							
<b>Number of affected second-degree relatives with breast cancer</b>							
	104	86.7	5	83.3	99	86.8	0.585
<b>0</b>	14	11.7	1	16.7	13	11.4	
<b>1</b>	2	1.7	0	0	2	1.8	
<b>≥ 2</b>							
<b>Number of affected first-degree relatives with ovarian cancer</b>							
	115	95.8	5	83.3	110	96.5	0.230
<b>0</b>	5	4.2	1	16.7	4	3.5	
<b>≥ 1</b>							
<b>Number of affected second-degree relatives with ovarian cancer</b>							
	118	98.3	5	83.3	113	99.1	0.098
<b>0</b>	2	1.7	1	16.7	1	0.9	
<b>≥ 1</b>							



Vital status							
<b>Alive</b>	95	79.2	4	66.7	91	79.8	0.603
<b>Deceased</b>	25	20.8	2	33.3	23	20.2	

274 <sup>a</sup> Mann-Whitney test or Fisher's Exact test whichever appropriate

275 <sup>b</sup> Statistically significant *p*-values are indicated in bold

276 <sup>c</sup> inclusive of breast, ovarian and other cancers

277

## 278 Discussion

279 Prior to introducing cancer genetic test in a community, genetic variation profile of the said community  
280 must first be known to have an overview of the contribution of genetics in the population. Although  
281 cancer incidence and mortality in Brunei Darussalam have been increasing for the past 10 years, there  
282 are still no data available on the proportion of Brunei cancer patients carrying germline or somatic  
283 mutations in their cancer predisposing gene. *BRCA1* and *BRCA2* gene frequencies in breast and ovarian  
284 cancer patients in other East-Asian populations have been continuously researched on which had led to  
285 the discovery of potential founder mutations [29,39,55,65]. Notably, identifying who should be offered  
286 cancer genetic test in the Asian community remains challenging as the currently available guidelines for  
287 testing have been shown to omit at least 20% of patients carrying *BRCA* mutations from being tested  
288 [21], suggesting the testing criteria on *BRCA1* and *BRCA2* germline mutations which have been well  
289 established in the Caucasian population were not readily applicable to the Asian population.

290 Our study, which is the first genetic study of its kind in Brunei, showed that the overall  
291 combined frequency of germline pathogenic *BRCA1* and *BRCA2* mutation carriers among 120 recruited  
292 Brunei's breast cancer patients was 5% ( $n = 6$ ), which is lower than those reported at 12.3% in women of  
293 European descent [66]. Our data are relatively similar to previously reported prevalence from other

294 Asian countries in particular from the South-East Asian region which is 4.7% in Malaysia [21] and 5.1% in  
295 the Philippines [39] except for Singapore [19] and Vietnam [40] which were reported at 17.4% and 0.8%,  
296 respectively. Interestingly, other Asian countries outside of the South-East Asian region had reported a  
297 relatively higher prevalence of *BRCA1* and *BRCA2* mutations which was almost similar (or higher for  
298 some) to the findings reported in European women with 14.0% in Korea [67] and 24.7% in Pakistan [68].  
299 Japan [69], Hong Kong [54,55] and China [20] however, reported a prevalence of 4.2%, 7.9% to 8.8%,  
300 and 8.3%, respectively. Comparatively, all these countries had reported prevalence of germline  
301 mutations in both *BRCA1* and *BRCA2* genes while all germline *BRCA* mutations identified in our study  
302 were attributed to *BRCA2* gene only. Our findings were consistent with those from all the  
303 aforementioned Asian countries where most of the germline pathogenic *BRCA* mutations in the Brunei  
304 breast cancer patients were identified in the *BRCA2* gene compared to *BRCA1* which was reported to be  
305 more affected in the European women [66].

306 Our study showed that one recurrent deleterious frameshift mutation, *BRCA2*c.5164\_5165delAG  
307 (S1722Yfs\*1725), was identified in 3 (2.5%) patients of Chinese ethnicity. In particular two of the  
308 affected patients, 4G-004 and 4G-003, were related to each other (mother and daughter, respectively).  
309 This mutation was suggested to have a founder effect in the Southern China province population. While  
310 it was unknown whether our Chinese index cases ancestry were originally from the Southern China,  
311 there was still a probability that the occurrence of this mutation might be linked to a common ancestral  
312 origin. Moreover, this mutation has also been reported in the Chinese ethnicity in Malaysia [34] and  
313 Singapore [18] which further support the probability of the founder mutation theory. However, it is  
314 acknowledged that the probability could be slightly lowered due to the fact that two out of three of the  
315 carriers of this mutation were relatives where the variant could have been inherited from their maternal  
316 side. Although the other two deleterious frameshift *BRCA2* mutations identified in this study only occur  
317 in one (0.8%) of the study population, the mutations c.3170\_3174delAGAAA (K1057Tfs\*1064) and

318 c.1763\_1766delATAAA (N588Sfs\*612) had each been reported as a founder mutation in the French-  
319 Canadian [52]and Colombian[51] populations respectively. The probability of these two mutations being  
320 linked to the two populations was highly unlikely as the carriers were both of Malay ethnicity, and the  
321 family history from both carriers did not support a common ancestral origin with the aforementioned  
322 populations. Interestingly, in the South-East Asia (SEA) population, the *BRCA2* mutation  
323 c.1763\_1766delATAA (N588Sfs\*612) was only ever reported in a breast cancer patient in Sarawak,  
324 Malaysia who was diagnosed <40 years old with triple negative breast cancer and family history of  
325 breast cancer [33].This observation suggests that all populations have different population genetic  
326 predisposition towards breast cancer. Pathogenic mutations determined as a founder effect in one  
327 population may only be detected in a small frequency in other populations of different ancestral origin.  
328 Moreover, for the two patients identified with these mutations, there is a 50% chance that their family  
329 members carried the same *BRCA2* mutation that could result in the development of breast cancer in  
330 these family members.

331         The three aforementioned frameshift mutations introduced premature stop codon which was  
332 known to be associated with an increased risk of breast cancer. The effect of frameshift mutations  
333 resulting in the stop codon has been shown to destabilise *BRCA* mRNA leading to a haplo-insufficiency  
334 resulting in allelic imbalance [70]. This in turn caused a significant reduction in the expression ratio  
335 between the mutant and the wild-type alleles [70]. The allelic imbalance resulted in a decreased level of  
336 both *BRCA* transcripts and proteins contributing to the increased risk of breast cancer [70].The resulting  
337 *BRCA2* truncated protein from the three identified pathogenic variants in our study showed a loss of  
338 important domains, including: (1) the BRC repeats domain (all for c.1763\_1766delATAAA, BRC-2 to BRC-  
339 8 for c.3170\_3174delAGAAA, BRC-6 to BRC-8 for c.5164\_5165delAG); (2) the DNA binding domain  
340 (DBD); and (3) the two nuclear localisation signals (NLS) in the C-terminus region (S2 Fig).The highly  
341 conserved eight BRC repeat domains and the DNA binding domains in the *BRCA2* protein mediate the

342 interaction of ssDNA and/or dsDNA with RAD51 molecules in the homologous recombination (HR)  
343 regulated DNA repair pathway. In HR regulated pathway, BRCA2 is localised onto sites of dsDNA break  
344 by forming complex with other proteins including BRCA1 and PALB2, before it mediates the loading of  
345 RAD51 onto the ssDNA and initiate the repair. Loss of these RAD51-interacting domains in the BRCA2  
346 protein prevent DNA repair in error-free HR regulated pathway, allowing the error-prone non-  
347 homologous end joining (NHEJ) pathway to take over. Moreover, it has been demonstrated that the  
348 deletions of all RAD51-interacting domains cause embryonic lethality in mice, but deletion of several  
349 BRC repeats motif showed a less severe phenotype although it was observed that the mice died very  
350 young from cancer development [71]. The DBD in BRCA2 was also involved in transcriptional activity  
351 where it bound ssDNA before drawing histone modifiers which led to the initiation of the transcriptional  
352 process [10]. The loss of the two NLS in the C-terminus region due to the truncation was reported to  
353 result in the mutant BRCA2 being cytoplasmic since it could not be translocated into the nucleus, hence  
354 causing it to become non-functional [72].

355         One likely pathogenic missense mutation was identified in the only patient who have no family  
356 history of cancers at all (S5 Table). *BRCA2* mutation c.8524C>T (R2842C) was located in the BRCA2 DNA  
357 binding domain suggesting it can affect the protein function. An assessment made on the clinical  
358 relevance of VUS identified in the BRCA2 DBD by using a validated functional assay of BRCA2  
359 homologous recombination (HR) DNA-repair activity had showed the mutation R2842C had  
360 intermediate or partial effects on BRCA2 function [57]. Another functional assessment of human *BRCA2*  
361 variants using a mouse embryonic stem cell (mESC)-based assay supported that although the mutation  
362 R2842C is able to complement the loss of cell viability, its capacity to perform BRCA2 function i.e.,  
363 homology directed repair (HDR) showed more than 50% reduction in HDR capacity compared with wild-  
364 type BRCA2 expressing cells[58,59]. These results suggested that the mutation R2842C is characterized  
365 as a hypomorphic variant in which the studies concluded that the mutation is intermediate between

366 pathogenic and likely pathogenic variants [58,59]. In our study, the effect of the hypomorphic *BRCA2*  
367 germline mutation R2842C was observed in patient 2G-022, in which the patient had an increased  
368 susceptibility to familial breast and/or ovarian cancers even though she did not have any family history  
369 of cancers at all. Notably, none of the founder mutations found in the SEA population were identified in  
370 our study population.

371         Similar to other genetic variation analysis conducted in other populations, 41 (43.2%) of the  
372 identified variants in the study population were classified as VUS (S3 Table). The overall combined  
373 frequency of patients with *BRCA1* and *BRCA2* VUS in the study was 35 (29.2%), in which 6 patients have  
374 both *BRCA1* and *BRCA2* VUS. Our findings are higher than those reported in other populations, such as  
375 5.7% in European [66], and 1.6% in Malaysian [21] women, respectively. It has been shown that the  
376 prevalence of VUS in a study population was inversely correlated with the total number of individuals  
377 tested [66]. Hence, if our total study cohort population was higher than 120, our prevalence could be  
378 relatively similar with other countries' findings as demonstrated in three other Asian countries' studies  
379 conducted comprising over 2500 breast cancer patients; namely China [20], Malaysia [21], and Japan  
380 [69].

381         Collectively, Brunei *BRCA2* carriers exhibited almost the same phenotypic association pattern as  
382 other *BRCA2* carriers in China [20] and Malaysia [21], where Brunei *BRCA2* carriers were found to be  
383 more likely to have family history of breast and/or ovarian cancers, and having more first-degree  
384 relatives affected with breast cancer. Consistent with other studies, our findings showed that TNBC is  
385 not significantly associated with *BRCA2* carriers [17,19,21].

386         It is acknowledged that this study is limited by the small size of the study population even  
387 though it was the first and largest cohort study for genetic testing in Brunei. Future study on a larger  
388 cohort of study population could confirm our findings on the prevalence of germline mutations in the  
389 Brunei breast cancer population. Moreover, it could also provide a more comprehensive data for

390 phenotypic characteristics of predisposing carriers in our breast cancer population attributed to each  
391 gene. Our current study showed that none of our study population tested for *BRCA1* and *BRCA2* large  
392 rearrangements showed positive for the test. Therefore, there are no data on the contribution of large  
393 rearrangement of *BRCA1* and *BRCA2* in the Brunei breast cancer population presented in this thesis.  
394 Given the constraint in getting resources for performing large rearrangements analysis in some of the  
395 study population (Batch 2), there is an approximately 10% probability that some carriers may have been  
396 missed in this study [19].

397

## 398 **Conclusions**

399 The findings from this study have highlighted the contribution of genetics, specifically *BRCA1* and *BRCA2*  
400 genes in 120 unselected series of Brunei breast cancer population. The prevalence of germline *BRCA1*  
401 and *BRCA2* mutation carriers among Brunei breast cancer patients (5%) is similar to that of other Asian  
402 populations confirming the difference in contribution of *BRCA1* and *BRCA2* in both the Caucasian and  
403 Asian populations. One *BRCA2* mutation observed only in Brunei breast cancer population of Chinese  
404 ethnicity contributes to the probability of the mutation being a founder effect in the Southern Chinese  
405 population. Future studies should investigate the contribution of germline mutations of *BRCA1* and  
406 *BRCA2* genes in a larger case-control cohort study of Brunei breast cancer population to confirm our  
407 findings.

408

## 409 **Acknowledgements**

410 We sincerely acknowledge all the doctors, nurses and staff from TBCC for their cooperation and also to  
411 CRM and First Base Laboratories Sdn Bhd for their contribution to the study. We would like to thank our  
412 undergraduate students; Jacinda Lim Xin Yan and Hon Kar Yee; who have taken a small project under

413 this study. Finally, we would like to express our gratitude to all patients who have participated in our  
414 research study. MRWHAH received a grant from Universiti Brunei Darussalam to fund the initial part of  
415 this study [UBD/PNC2/2/RG/1(186)]

416

## 417 **References**

- 418 1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M, et al. Estimating the global  
419 cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer*.  
420 2019;144:1941-53. doi: <https://doi.org/10.1002/ijc.31937>
- 421 2. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and  
422 progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular  
423 pathogenesis. *Genes Dis*. 2018;5:77-106. doi: <https://doi.org/10.1016/j.gendis.2018.05.001>
- 424 3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, et al. A strong candidate  
425 for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science*. 1994;266(5182):66-71.
- 426 4. Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer  
427 susceptibility gene, *BRCA2*, to chromosome 13q12-13. *Science*. 1994;265:2088-90.
- 428 5. Xu B, Kim S, Kastan M. Involvement of *Brca1* in S-Phase and G2-Phase checkpoints after ionizing  
429 irradiation. *Mol Cell Biol*. 2001;21(10):3445-50.
- 430 6. Starita L, Parvin J. The multiple nuclear functions of *BRCA1*: transcription, ubiquitination and DNA  
431 repair. *Curr Opin Cell Biol*. 2003;15:345-50.
- 432 7. Davies O, Pellegrini L. Interaction with the *BRCA2* C-terminus protects RAD51-DNA filaments from  
433 disassembly by BRC repeats. *Nat Struct Mol Biol*. 2007;14:475-83. doi:10.1083/nsmb1251.

- 434 8. Tassone P, Di Martino M, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of *BRCA1*  
435 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.  
436 *Cancer Biol Ther.* 2009;8(7):648-53.
- 437 9. Clark S, Rodriguez A, Snyder R, Hankins G, Boehning D. Structure-Function of the tumor suppressor  
438 *BRCA1*. *Comput Struct Biotech.* 2012;1(1):e201204005.
- 439 10. Orr KS, Savage KI. The *BRCA1* and *BRCA2* Breast and Ovarian Cancer Susceptibility Genes –  
440 Implications for DNA Damage Response, DNA Repair and Cancer Therapy. In: Chen C, editors.  
441 *Advances in DNA Repair*. London: IntechOpen; 2015. p. 217-53.
- 442 11. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of Serine 1387 in *Brca1* is specifically  
443 required for the Atm-mediated S-Phase checkpoint after ionizing irradiation. *Cancer Res.*  
444 2002;62:4588-91.
- 445 12. Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, et al. *BRCA1-BARD1* complexes  
446 are required for *p53*<sup>Ser-15</sup> phosphorylation and a G1/S arrest following ionizing radiation-induced  
447 DNA damage. *J Biol Chem.* 2004;279(30):31251-8.
- 448 13. Deng CX. *BRCA1*: cell cycle checkpoint, genetic instability, DNA damage response and cancer  
449 evolution. *Nucleic Acids Res.* 2006;34(5):1416-26.
- 450 14. Park MA, Seok YJ, Jeong G, Lee JS. SUMO1 negatively regulates *BRCA1*-mediated transcription, via  
451 modulation of promoter occupancy. *Nucleic Acids Res.* 2008;36(1):263-83. doi:10.1093/nar/gkm969.
- 452 15. Roy R, Chun J, Powell SN. *BRCA1* and *BRCA2*: different roles in a common pathway of genome  
453 protection. *Nat Rev Cancer.* 2016;12(1):68-78.
- 454 16. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, the *BRCA1* and  
455 *BRCA2* Cohort Consortium. Risks of breast, ovarian and contralateral breast cancer for *BRCA1* and  
456 *BRCA2* mutation carriers. *JAMA.* 2017;317(23):2402-16. doi:10.1001/jama.2017.7112.



- 457 17. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of  
458 breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium  
459 of Investigators of Modifiers of *BRCA1/2* (CIMBA). *Cancer Epidemiol Biomarkers Prev*. 2012;21(1):134-47.  
460 doi:10.1158/1055-9965.EPI-11-0775.
- 461 18. Wong ESY, Shekar S, Chan CHT, Hong LZ, Poon SY, Silla T, et al. Predictive Factors for *BRCA1* and  
462 *BRCA2* Genetic Testing in an Asian Clinic-Based Population. *PLoS ONE*. 2015;10(7):e0134408.
- 463 19. Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al. Inherited breast cancer  
464 predisposition in Asians: multigene panel testing outcomes from Singapore. *Genom Med*.  
465 2016;1:15003. doi:10.1038/npjgenmed.2015.3.
- 466 20. Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, et al. The spectrum of *BRCA*-associated breast  
467 cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. *Int J*  
468 *Cancer*. 2017;141:129-42.
- 469 21. Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, et al. Inherited mutations in *BRCA1* and  
470 *BRCA2* in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls  
471 from Malaysia. *J Med Genet*. 2018;55:97-103. doi:10.1136/jmedgenet-2017-104947.
- 472 22. Wallace AJ. New challenges for BRCA testing: a view from the diagnostic laboratory. *Eur J Hum*  
473 *Genet*. 2016;24:S10-8. doi:10.1038/ejhg.2016.94.
- 474 23. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast  
475 cancer in patients with a germline *BRCA* mutation. *New Engl J Med*. 2017;377:523-33.  
476 doi:10.1056/NEJMoa1706450.
- 477 24. Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, et al. Biological and clinical evidence  
478 for somatic mutations in *BRCA1* and *BRCA2* as predictive markers for Olaparib response in high-  
479 grade serous ovarian cancers in the maintenance setting. *Oncotarget*. 2017;8(27):43653-61.

- 480 25. Department of Economic Planning and Development (DEPD). Brunei Darussalam key indicators  
481 (BDKI) [Internet]. Brunei Darussalam: DEPDP; 2018 [accessed 2019 Mar 21]. Available from:  
482 [http://www.depd.gov.bn/DEPD%20Documents%20Library/DOS/BDKI/BDKI\\_2018.pdf](http://www.depd.gov.bn/DEPD%20Documents%20Library/DOS/BDKI/BDKI_2018.pdf)
- 483 26. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018:  
484 GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Ca-*  
485 *Cancer J Clin.* 2018;68:394-424.
- 486 27. Chong VH, Telisinghe PU. Rising incidence of breast cancer in Brunei Darussalam. *Brunei Int Med J.*  
487 2011;7(5):260-8.
- 488 28. Tan S, Abdullah MS, Telisinghe PU, Ramasamy R. Breast cancer in Brunei Darussalam – Incidence and  
489 the role of evaluation of molecular markers. *Brunei Int Med J.* 2011;7(5):250-9.
- 490 29. SngJH, Ali AB, Lee SC, Zahar D, Wong JEL, Blake V, et al. *BRCA1* c.2845insA is a recurring mutation  
491 with a founder effect in Singapore Malay women with early onset breast/ovarian cancer. *J Med*  
492 *Genet.* 2003;40:e117.
- 493 30. Ho GH, Phang BH, Ng ISL, Law HY, Soo KC, Ng EH. Novel Germline *BRCA1* Mutations Detected in  
494 Women in Singapore who Developed Breast Carcinoma before the Age of 36 Years. *Cancer.*  
495 2000;89:811-6.
- 496 31. Lim YL, Iau PTC, Ali AB, Lee SC, Wong JEL, Putti TC, et al. Identification of novel *BRCA* large genomic  
497 rearrangements in Singapore Asian breast and ovarian patients with cancer. *Clin Genet.*  
498 2007;71:331-342.
- 499 32. Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, et al. Evaluation of *BRCA1* and *BRCA2*  
500 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low  
501 incidence of breast cancer. *Breast Cancer Res.*2008;10:R59. doi:10.1186/bcr2118.

- 502 33. Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, Xiao Y, et al. Prevalence and spectrum of germline  
503 rare variants in *BRCA1/2* and *PALB2* among breast cancer cases in Sarawak, Malaysia. *Breast Cancer*  
504 *Res Treat.* 2017;165(3):687-97. doi:10.1007/s10549-017-4356-8.
- 505 34. Ng PS, Wen WX, Fadlullah MZH, Yoon SY, Lee SY, Thong MK, et al. Identification of germline  
506 alterations in breast cancer predisposition genes among Malaysian breast cancer patients using  
507 panel testing. *Clin Genet.* 2016. doi: 10.1111/cge.12735.
- 508 35. Balraj P, Khoo ASB, Volpi L, Tan JAMA, Nair S, Abdullah H. Mutation Analysis of the *BRCA1* Gene in  
509 Malaysian Breast Cancer Patients. *Singapore Med J.* 2002;43(4):194-7.
- 510 36. Toh GT, Kang P, Lee SSW, Lee DSC, Lee SY. *BRCA1* and *BRCA2* Germline Mutations in Malaysian  
511 Women with Early-Onset Breast Cancer without a Family History. *PLoS ONE.* 2008;3(4):e2024.  
512 doi:10.1371/journal.pone.0002024.
- 513 37. Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, et al. Large *BRCA1* and *BRCA2* genomic  
514 rearrangements in Malaysian high-risk breast-ovarian cancer families. *Breast Cancer Res*  
515 *Treat.* 2010;124:579-84.
- 516 38. Tria IV F, Ang D, Andal JJ, Que FV, Cabral LK, Dimalibot R, et al. Prevalence of Germline *Brca1* and  
517 *Brca2* Mutation Among Filipinos. *Cancer Res J.* 2019;7(3):79-86. doi: 10.11648/j.crj.20190703.12
- 518 39. Matsuda MLDL, Liede A, Kwan E, Mapua CA, Cutiongco EMC, Tan A, et al. *BRCA1* and *BRCA2*  
519 mutations among breast cancer patients from the Philippines. *Int. J. Cancer.* 2002;98:596-603.
- 520 40. Ginsburg OM, Dinh NV, To TV, Quang LH, Linh ND, Duong BTH, et al. Family history, *BRCA* mutations  
521 and breast cancer in Vietnamese women. *Clin Genet.* 2010. doi: 10.1111/j.1399-0004.2010.01545.x.
- 522 41. Thuan TV, Chu NV, Khoa PH, Quang NT, Tu DV, Tho NTQ, et al. A Novel *BRCA1* Gene Mutation  
523 Detected with Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A  
524 Case Report. *Breast Cancer Basic Clin Res.* 2020;14:1-4. doi: 10.1177/1178223420901555

- 525 42. Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, MethakijvaroonS, Badzioch M, et al.  
526 Analysis of Breast Cancer Susceptibility Genes *BRCA1* and *BRCA2* in Thai Familial and Isolated Early-  
527 Onset Breast and Ovarian Cancer. *Hum Mutat.* 2002;520. doi: 10.1002/humu.9049
- 528 43. Jadsri S, Chareonsirisuthigul T, Rerkamnuaychoke B, Dejsuphong D, Tunteeratum A,  
529 Mahasirimongkol S. *BRCA1* and *BRCA2* Large Genomic Rearrangements Screening in Thai Familial  
530 Breast Cancer Patients by Multiplex Ligation-dependent Probe Amplification (MLPA). *Naresuan*  
531 *University Journal: Science and Technology.* 2016;24(2).
- 532 44. Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ. A novel *BRCA2* mutation in an  
533 Indonesian family found with a new, rapid, and sensitive mutation detection method based on  
534 pooled denaturing gradient gel electrophoresis and targeted sequencing. *J Clin Path.* 2005;58:493-9.  
535 doi:10.1136/jcp.2004.020388
- 536 45. Purnomosari D, Pals G, Wahyono A, Aryandono T, Manuaba TW, Haryono SJ, et al. *BRCA1* and *BRCA2*  
537 germline mutation analysis in the Indonesian population. *Breast Cancer Res Treat.* 2007;106:297-  
538 304.
- 539 46. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of *BRCA1* by  
540 analysis of germline mutations linked to breast and ovarian cancer in ten families. *Nat*  
541 *Genet.* 1994;8:399–404.
- 542 47. Wagner T, Stoppa-Lyonnet D, FleischmannE, Muhr D, Pages S, Sandberg T, et al. Denaturing high-  
543 performance liquid chromatography detects reliably *BRCA1* and *BRCA2* mutations.  
544 *Genomics.* 1999;62(3):369-76.
- 545 48. MaloneKE, Daling JR, DoodyDR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of  
546 *BRCA1* and *BRCA2* mutations in a population-based study of breast cancer in white and black  
547 American women ages 35 to 64 years. *Cancer Res.* 2006;66(16):8297–308.

- 548 49. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Čech M, et al. The Galaxy platform for  
549 accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids*  
550 *Res.*2018;46(W1):W537-44. doi:10.1093/nar/gky379.
- 551 50. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the  
552 interpretation of sequence variants: a joint consensus recommendation of the American College of  
553 Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.*  
554 2015;17:405-23. doi:<https://doi.org/10.1038/gim.2015.30>
- 555 51. Torres D, Bermejo JL, Rashid MU, Briceño I, Gil F, Beltran A, et al. Prevalence and Penetrance of  
556 *BRCA1* and *BRCA2* Germline Mutations in Colombian Breast Cancer Patients. *Nat Sci*  
557 *Rep.*2017;7:4713. doi:10.1038/s41598-017-05056-y.
- 558 52. Janavičius R. Founder *BRCA1/2* mutations in the Europe: implications for hereditary breast-ovarian  
559 cancer prevention and control. *EPMA Journal*, 2010;1:397-412.
- 560 53. Sun J, Meng H, Yao L, Meng L, Bai J, Zhang J, et al. Germline mutations in cancer susceptibility genes  
561 in a large series of unselected breast cancer patients. *Clin Cancer Res.* 2017;23(20):6113-9. doi:  
562 10.1158/1078-0432.CCR-16-3227.
- 563 54. Kwong A, Shin VY, Au CH, Law FBF, Ho DN, Ip BK, et al. Detection of Germline Mutation in Hereditary  
564 Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. *J Mol Diagn.*  
565 2016;18:580-94. doi: <http://dx.doi.org/10.106/j.jmoldx.2016.03.005>.
- 566 55. Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, et al. Rapid detection of *BRCA1/2*  
567 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot  
568 genotyping panel. *Oncotarget.* 2018;9(8):7832-43.
- 569 56. Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, et al. A classification model for  
570 *BRCA2* DNA binding domain missense variants based on homology directed repair activity. *Cancer*  
571 *Res.* 2013;73(1):265-75. doi:10.1158/0008-5472.CAN-12-2081.

- 572 57. Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, et al. Assessment of the clinical  
573 relevance of *BRCA2* missense variants by functional and computational approaches. *Am J Hum*  
574 *Genet.* 2018; 102: 233-48.
- 575 58. Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, et al. The functional impact  
576 of variants of uncertain significance in *BRCA2*. *Genet Med.* 2019; 21: 293-302. doi:  
577 <https://doi.org/10.1038/s41436-018-0052-2>
- 578 59. Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, et al. Homozygous  
579 hypomorphic *BRCA2* variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait.  
580 *J Med Genet.* 2020; 0: 1-10. doi:10.1136/jmedgenet-2019-106672.
- 581 60. Bouwman P, van der Gulden H, van der Heiden I, Drost R, Klijn CN, Prasetyanti P, et al. A high-  
582 throughput functional complementation assay for classification of *BRCA1* missense variants. *Cancer*  
583 *Discov.* 2013; 3(10): 1142-55. doi:10.1158/2159-8290.CD-13-0094.
- 584 61. Xu GP, Zhao Q, Wang D, Xie WY, Zhang LJ, Zhou H, et al. The association between *BRCA1* gene  
585 polymorphism and cancer risk: a meta-analysis. *Oncotarget.* 2018; 9(9): 8681-94.
- 586 62. Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, et al. Identification of a novel *BRCA1* pathogenic  
587 mutation in Korean patients following reclassification of *BRCA1* and *BRCA2* variants according to the  
588 ACMG Standards and Guidelines using relevant ethnic controls. *Cancer Res Treat.* 2017; 49(4): 1012-  
589 21. doi: <https://doi.org/10.4143/crt.2016.433>
- 590 63. Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, et al. Accurate classification of  
591 *BRCA1* variants with saturation genome editing. *Nature.* 2018; 562(7726): 217-22.  
592 doi:10.1038/s41586-018-0461-z.
- 593 64. Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, et al. Kin-cohort  
594 estimates for familial breast cancer risk in relation to variants in DNA base excision repair, *BRCA1*  
595 interacting and growth factor genes. *BMC Cancer.* 2004; 4(9).

- 596 65. Karami F, Mehdipour P. A comprehensive focus on global spectrum of *BRCA1* and *BRCA2* mutations in  
597 Breast Cancer. *Biomed Res Int*. 2013; 1-21.
- 598 66. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. *BRCA1* and *BRCA2* mutations  
599 in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.  
600 *Cancer*. 2009; 115(10): 2222-33. doi: 10.1002/cncr.24200.
- 601 67. Kim HN, Shin MH, Lee R, Park MH, Kweon SS. Novel Germline Mutations of *BRCA1* and *BRCA2* in  
602 Korean Familial Breast Cancer Patients. *Chonnam Med J*. 2019; 55: 99-103.  
603 <https://doi.org/10.4068/cmj.2019.55.2.99>.
- 604 68. Rashid MU, Muhammad N, Naeemi H, Khan FA, Hassan M, Faisal S, et al. Spectrum and prevalence  
605 of *BRCA1/2* germline mutations in Pakistani breast cancer patients: results from a large  
606 comprehensive study. *Hered Cancer in Clin Pr*. 2019; 17(27). doi: [https://doi.org/10.1186/s13053-](https://doi.org/10.1186/s13053-019-0125-5)  
607 [019-0125-5](https://doi.org/10.1186/s13053-019-0125-5).
- 608 69. Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, et al. Germline pathogenic  
609 variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. *Nature Comm*.  
610 2018; 9: 4083. doi: 10.1038/s41467-018-06581-8.
- 611 70. Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, et al. Intronic alterations in *BRCA1*  
612 and *BRCA2*: effect on mRNA splicing fidelity and expression. *Hum Mutat*. 2006; 27(5): 427-435.
- 613 71. Donoho G, Brenneman MA, Cui TX, Donoviel D, Vogel H, Goodwin EH, et al. Deletion of *Brca2* exon  
614 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.  
615 *Gene Chromosome Canc*. 2003; 36: 317-31. doi: <https://doi.org/10.1002/gcc.10148>.
- 616 72. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. Truncated *BRCA2* is cytoplasmic:  
617 Implications for cancer-linked mutations. *PNAS*. 1999; 96(24): 13920-5.  
618  
619

## 620 **Supporting information**

621 **S1 Fig. The study strategy to detect *BRCA1* and *BRCA2* mutations.**

622 **S2 Fig. Schematic presentation of truncated *BRCA2* protein in the study population.** The three

623 identified *BRCA2* pathogenic mutations, c.1763\_1766delATAAA, c.3170\_3174delAGAAA and

624 c.5164\_5165delAG led to *BRCA2* protein truncation at amino acids positions 612, 1064, and 1725

625 respectively. The truncation caused the loss of important domains affecting the function of *BRCA2*

626 predominantly in the HR-regulated DNA repair pathway.

627 **S1 Table. Deleterious mutations identified in the Brunei breast cancer patients.\***, Termination; AA,

628 amino acid; AF, Allele Frequency; Freq, Frequency; FS, Frameshift; Nov, Novel; Ref, Reference; Rep,

629 Reported.

630 **S2 Table. Damaging missense variants identified in the Brunei breast cancer patients.** AA, amino acid;

631 AF, Allele Frequency; B, Benign; D, Damaging; Freq, Frequency; N, Neutral; NA, Not Available; Nov,

632 Novel; PrD, Probably Damaging; Ref, Reference; Rep, Reported; T, Tolerated.

633 **S3 Table. Missense variants identified in the Brunei breast cancer patients.** AA, amino acid; AF, Allele

634 Frequency; B, Benign; D, Damaging; Freq, Frequency; N, Neutral; NA, Not Available; Nov, Novel; PoD,

635 Possibly Damaging; PrD, Probably Damaging; Ref, Reference; Rep, Reported; T, Tolerated; VUS, Variant

636 of uncertain significance.

637 **S4 Table. Synonymous variants identified in the Brunei breast cancer patients.** AA, amino acid; AF,

638 Allele Frequency; Freq, Frequency; NA, Not Available; Nov, Novel; Rep, Reported.

639 **S5 Table. Characteristics of the Brunei breast cancer patients with deleterious and damaging missense**


640 **mutations.**+, Positive; -, Negative; ^XX, year diagnosed or deceased; AA, Amino acid; Aff, Affected; Au,

641 Aunt; Bil., Bilateral; Br, Breast; Bro, Brother; Ca, Cancer; Chi, Chinese; Cou, Cousin; Dau, Daughter; de.,

642 deceased; dx., diagnosed; DC, Ductal carcinoma; DCIS, Ductal carcinoma in situ; ER, Oestrogen receptor;



643 Eth, Ethnicity; F, Female; Fa, Father; Gen, Gender; GrMo, Grandmother; Her2, Human Epidermal Growth  
644 Receptor-2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; L, Left; Liv, Liver; Lu, Lung;  
645 M, Male; Mal, Malay; Mat, Maternal; Mo, Mother; O, Older; Ov, Ovarian; Pat, Paternal; PR,  
646 Progesterone receptor; R, Right; Rec, Rectal; Sis, Sister; Sync, Synchronous; Uni, Unilateral; Y, Younger;  
647 yr., years.



Figure